Illumina Inc Stock Price, News & Analysis

Illumina (NASDAQ: ILMN) announced the acquisition of GRAIL, a company focused on early cancer detection, holding GRAIL separate during ongoing EU regulatory reviews. The acquisition aims to expedite global access to GRAIL's Galleri blood test, which can identify 50 cancers early. The transaction involves approximately $3.5 billion and around 11.3 million shares of Illumina stock. Illumina asserts that this merger could save lives and improve healthcare economics, although it faces regulatory scrutiny in both the EU and the US.

Illumina, Inc. (NASDAQ: ILMN) reported record revenue of $1,126 million for Q2 2021, a 78% increase year-over-year. GAAP net income reached $185 million ($1.26 per diluted share) compared to $47 million ($0.32) in the same period last year. Non-GAAP net income was $276 million ($1.87 per diluted share), a significant rise from $92 million ($0.62) a year prior. The company raised its 2021 financial guidance, expecting revenue growth between 32% to 34% and GAAP EPS of $4.69 to $4.89.

Illumina (NASDAQ: ILMN) has announced a $1 million donation to enhance SARS-CoV-2 sequencing at Kasturba Hospital in Greater Mumbai, aiding genomic surveillance across India. This contribution includes two NextSeq™ 2000 NGS platforms, reagents, and four years of service support. CEO Francis deSouza emphasized the importance of democratizing access to sequencing technology in regions burdened by infectious diseases. The initiative aims to support COVID-19 control efforts through advanced genomic capabilities.

Illumina (NASDAQ: ILMN) executives will participate in the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021. The fireside chat is scheduled for 12:00 pm PT (3:00 pm ET). Investors can access the live webcast via the Investor Info section on www.illumina.com, with a replay available for 30 days post-event. Illumina focuses on innovations in DNA sequencing and array-based technologies, enhancing applications in life sciences, oncology, and more.

Illumina (NASDAQ: ILMN) has reaffirmed its commitment to acquire GRAIL, a leader in multi-cancer early detection technology. The company is actively collaborating with the European Commission to address concerns regarding the merger. Illumina is also contesting the Commission’s jurisdiction to review the merger under EU laws. CEO Francis deSouza emphasized that the acquisition would expedite access to life-saving cancer screenings in Europe, potentially saving tens of thousands of lives and reducing healthcare costs. The deal reflects Illumina's strategy to enhance its market position in genomic health.

Illumina, Inc. (NASDAQ: ILMN) is set to release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call with CEO Francis deSouza and CFO Sam Samad will follow at 2:00 PM PT (5:00 PM ET) to discuss the financial results. Investors can access the call via the company’s website or by dialing in. A replay will be available online for 30 days post-event. As a leader in DNA sequencing and array-based technologies, Illumina focuses on enhancing human health through genomic insights.

The DNA Data Storage Alliance, created by Twist Bioscience (TWST), Illumina (ILMN), and Western Digital (WDC), has published a white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.” This document discusses DNA storage's potential to address the exponential growth of digital data, highlighting that humans generated over 400 ZB of data in 2020. The paper outlines DNA's unprecedented storage density, stability, and sustainability compared to existing technologies. The Alliance aims to develop standards for interoperability in DNA storage solutions as the technology evolves.

Illumina (NASDAQ:ILMN) has partnered with Belgian Genetic Centers to assess whole-genome sequencing (WGS) for diagnosing patients with intellectual disabilities (ID) and developmental disorders (DD). The BeSolveRD study will recruit 800 pediatric patients and evaluate the economic impact of WGS versus existing care standards. Illumina will supply sequencing reagents, with the aim of influencing reimbursement decisions for WGS in routine clinical use. The study highlights WGS’s ability to identify genetic causes in rare developmental disorders.

Illumina (NASDAQ: ILMN) announced its executives will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. A fireside chat is scheduled for 7:30 am PT / 10:30 am ET. The event will be accessible via a live webcast on Illumina's website, with a replay available for at least 30 days post-event. Illumina is a leader in DNA sequencing and array-based technologies, focusing on improving human health through genomic innovation.